How much revenue does Changzhou Qianhong Biopharma make?

Changzhou Qianhong Biopharma reported 1.53 billion CNY in revenue for fiscal year 2024, down 15.9% from 1.81 billion CNY in fiscal year 2023. In Q2 2025 revenue was 410.89 million CNY.

What is Changzhou Qianhong Biopharma's largest business segment?

Biomedicine, with 1.53 billion CNY or 97% of segment revenue in fiscal year 2025. Next: Others (3%).

Where does Changzhou Qianhong Biopharma make most of its revenue?

China: 77% of revenue by region in fiscal year 2025, followed by Overseas (23%).

What companies are similar to Changzhou Qianhong Biopharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Chongqing Genrix Biopharmaceutical Co., Ltd. (688443.SS), Wanbangde Pharmaceutical Holding Group Co., Ltd. (002082.SZ), Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS), Beijing Foyou Pharma Co.,ltd (601089.SS).

Changzhou Qianhong Biopharma Co.,ltd (002550.SZ) Stock

About Changzhou Qianhong Biopharma Co.,ltd

Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase, as well as offers berry source and target diet box. It also provides low molecular weight heparin, compound digestive...

At a glance

Changzhou Qianhong Biopharma reported revenue of 1.53 billion CNY for fiscal year 2024, down 15.9% from fiscal year 2023, and net income of 356.03 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 410.89 million CNY, up 4.2% from a year before. Its largest business segment, Biomedicine, brought in 97% of segment revenue in fiscal year 2025; China was the largest region with 77%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.